When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Thomas Prebet, MD, PhD, Yale School of Medicine, previews recent advancements and treatment options for acute myeloid leukemia (AML) patients with TP53, IDH, and FLT3 mutations. Dr. Prebet…
Roger H. Kobayashi, MD, clinical professor at UCLA School of Medicine, discusses primary immunodeficiency in geriatric patients at the Immune Deficiency Foundation’s National Summit. Primary immunodeficiency is not…
Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, discusses acute myeloid leukemia (AML) in the context of the COVID-19 pandemic. The prevalence of healthcare disparities…
This week, CBS News reported that Moderna's early data from their vaccine trials show 94.5% efficacy, with 5 vaccine recipients included in the trial's 95 confirmed cases, and…
Hana Niebur, MD, assistant professor at the University of Nebraska Children’s Hospital and Medical Center, discusses non-infectious complications of primary immune deficiency. Lung disease is the most common…
Samuel I. Fink, MD, FACP, internal medicine specialist in private practice in Tarzana, California, and his daughter, Sarrica Fink, RN, previously in practice at Cedar Sinai Medical Center…
Jenny C. Yip, PsyD, ABPP, creator of Little Thinkers Center in Los Angeles, and author of Productive, Successful YOU!, offers tips on setting up for success when you…
Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, reviews treatment options for acute myeloid leukemia (AML) patients. Dr. Krivoshik states that, while patients traditionally receive…
Arkadiusz Z. Dudek, MD, medical oncologist at Regions Hospital Care Center in St. Paul, Minnesota, discusses a phase 2 trial of nivolumab plus ramucirumab in previously treated mesothelioma…
Researchers from UC Davis Comprehensive Cancer Center discuss results from their recent study on long term complications adolescents and young adults face after treatment for acute myeloid leukemia…
